Compare Clorox Co (CLX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs State Street SPDR S&P Biotech ETF — how do they compare? Clorox Co trades at $108.39 (market cap $13.09B), while State Street SPDR S&P Biotech ETF trades at $159.14. The key difference: Clorox Co pays a 4.62% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Clorox Co nearer its low. Which is the better fit depends on your goals.
| CLX | XBI | |
|---|---|---|
Market Cap | $13.09B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $127.16 | $164.28 |
52-Week Low | $86.12 | $86.92 |
Enterprise Value | $18.47B | — |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLX trades at $106.30, down 1.3% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $1.66, though Q4 2025 missed. The company reported FY2025 revenue of $7.10B and net income of $810M, with improving margins. A dividend increase to $1.25 per share was announced, payable in August 2026.
Outlook is mixed: strong profitability and dividend support value, but high P/E of 22.51 and modest revenue growth pose valuation concerns. Analyst consensus is cautious with a $97.50 price target below current levels. Risks include inflation pressures and competitive threats from private labels, limiting near-term upside potential.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
